5:35 PM
 | 
Aug 20, 2014
 |  BC Extra  |  Top Story

Amicus gains after Amigal meets in Phase III

Amicus Therapeutics Inc. (NASDAQ:FOLD) rose $0.93 (20%) to $5.50 on Wednesday after reporting that Amigal migalastat ( AT1001) met the co-primary endpoints of comparability to enzyme replacement therapy (ERT) on two measures of kidney function in the Phase III ATTRACT (Study 012) trial to treat Fabry's disease. The measures were mean annualized estimated glomerular filtration and...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >